RxDoctor Payments Data

Christopher Karcher, MD

Sleep Medicine · Ocean Springs, MSNPI 1194810408

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 1,487 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.

$25,906in general payments, 2019–2025

Across 1,487 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Acadia Pharmaceuticals Inc$2K
  • Amgen$2K
  • Novartis$2K
  • AstraZeneca$1K
  • plus $14K from 52 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$25,838100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)240$3,295
UCB, Inc.116$2,114
Acadia Pharmaceuticals Inc107$1,893
Amgen(2 entities)84$1,801
Novartis101$1,666
AstraZeneca(2 entities)67$1,282
SK Life Science, Inc.64$1,277
Teva Pharmaceuticals USA, Inc.79$1,187
Genentech USA, Inc.52$1,169
Pfizer64$890
Lundbeck LLC37$779
Biogen44$725
Sunovion Pharmaceuticals Inc.32$585
Eisai Inc.26$533
EMD Serono, Inc.28$491
Bristol Myers Squibb25$464
Neurocrine Biosciences, Inc.23$459
Inspire Medical Systems, Inc.12$416
Sanofi22$404
Argenx US, Inc.19$383
Lilly USA, LLC22$334
Supernus Pharmaceuticals, Inc.32$329
Microtransponder, Inc.2$246
Adamas Pharmaceuticals, Inc.14$234
Johnson & Johnson(2 entities)16$196
CSL Behring10$194
Arbor Pharmaceuticals, Inc.14$187
ANI Pharmaceuticals, Inc.9$170
Takeda Pharmaceuticals U.S.A., Inc.7$165
Biohaven Pharmaceutical Holding Company Ltd.11$164
Harmony Biosciences LLC10$158
Mallinckrodt Hospital Products Inc.9$149
Jazz Pharmaceuticals Inc.8$146
Avanir Pharmaceuticals, Inc.8$117
Merz Pharmaceuticals, LLC6$115
Neurelis, Inc.6$112
GE HealthCare7$107
Vanda Pharmaceuticals Inc.5$104
Upsher-smith Laboratories LLC6$103
TG Therapeutics, Inc.6$102
MDD US Operations, LLC6$88
Philips North America LLC1$74
Tanabe Pharma America, Inc.5$72
Amylyx Pharmaceuticals, Inc.3$61
Amneal Pharmaceuticals LLC4$60
Axsome Therapeutics, Inc.2$37
Revance Therapeutics, Inc.2$37
Apria Healthcare LLC2$35
Alnylam Pharmaceuticals Inc.2$34
Kyowa Kirin, Inc.1$24
Acorda Therapeutics, Inc2$23
Life Molecular Imaging Ltd1$23
Boston Scientific1$18
Collegium Pharmaceutical, Inc.1$18
Banner Life Sciences, LLC1$16
Portola Pharmaceuticals, LLC1$16
Otsuka America Pharmaceutical, Inc.1$13
Azurity Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few sleep medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$114,702
Medicare patients
653
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5040$406,730
GammakedImmune Globul G/Gly/Iga Avg 4617$284,940
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$178,609
NuplazidPimavanserin Tartrate13$66,493
Tetrabenazine13$4,580
Lacosamide18$1,216
Carbidopa-LevodopaCarbidopa/Levodopa30$903
Gabapentin54$764
Divalproex Sodium ErDivalproex Sodium16$662
Memantine Hcl22$292
Levetiracetam31$265
Sodium Chloride0.9 % Sodium Chloride14$255
Fluticasone Propionate19$247
Primidone14$219
Clonazepam17$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$194$406,73040 claims
Acadia Pharmaceuticals IncNuplazid$1,893$66,49313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other sleep medicine in Ocean Springs

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →